Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis
Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is driven by an overactive immune signaling pathway called type I interferon. Current treatment relies on broadly immunosuppressive agents that lack mechanistic specificity, often fail to achieve durable disease control, and can result in off-target toxicity and irreversible disease-related damage in many patients.…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
